These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 18853973)

  • 21. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK
    Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.
    Dudley-Brown S; Nag A; Cullinan C; Ayers M; Hass S; Panjabi S
    Gastroenterol Nurs; 2009; 32(5):327-39. PubMed ID: 19820441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of infliximab maintenance therapy on health-related quality of life.
    Feagan BG; Yan S; Bala M; Bao W; Lichtenstein GR
    Am J Gastroenterol; 2003 Oct; 98(10):2232-8. PubMed ID: 14572573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
    Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
    Reilly MC; Gerlier L; Brabant Y; Brown M
    Clin Ther; 2008 Feb; 30(2):393-404. PubMed ID: 18343277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
    Sandborn WJ; Colombel JF; Schreiber S; Plevy SE; Pollack PF; Robinson AM; Chao J; Mulani P
    Inflamm Bowel Dis; 2011 Jan; 17(1):141-51. PubMed ID: 20848500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
    N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.